Form 4: AMEDISYS Officer's Holdings Shift Post-UnitedHealth Merger

Amedisys Chief Accounting Officer Allyson Guidroz reports changes in her equity holdings following the company's acquisition by UnitedHealth Group on August 14, 2025.

Summary

• Allyson Guidroz, Chief Accounting Officer of Amedisys, Inc. (AMED), reported changes in her beneficial ownership due to the acquisition of Amedisys by UnitedHealth Group Incorporated.
• The merger became effective on August 14, 2025.
• Each outstanding share of Amedisys common stock was converted into the right to receive $101 per share in cash.
• Amedisys restricted stock units (RSUs) were converted into UnitedHealth Group RSUs, maintaining original terms.
• Amedisys stock options were converted into UnitedHealth Group options, also maintaining original terms, with exercise prices and share counts adjusted by an Equity Award Exchange Ratio.
• Guidroz disposed of 898 shares of common stock, 8,574 shares of common stock (converted to RSUs), and 1.5 shares from her 401(k) plan, all on August 14, 2025.
• She also disposed of fully vested stock options with exercise prices ranging from $95.76 to $264, which were converted into UnitedHealth Group options.
• Following these transactions, Guidroz holds 0 shares of Amedisys common stock directly or indirectly, and 0 Amedisys derivative securities.

Sentiment

Score: 7

Explanation: The filing reports the expected conversion of equity holdings of a Chief Accounting Officer following a pre-announced merger, indicating a smooth transition of ownership and equity awards as per the merger agreement.

Positives

• The merger provided a cash consideration of $101 per share for Amedisys common stock holders.
• Outstanding restricted stock units and stock options were converted into UnitedHealth Group equity awards, allowing for continued participation in the acquiring company's equity.
• The stock options converted were fully vested, ensuring their value was preserved in the conversion.

Negatives

• The reporting person no longer holds direct or indirect beneficial ownership in Amedisys, Inc. common stock or derivative securities, as the company is now a wholly-owned subsidiary of UnitedHealth Group.

Future Outlook

The filing indicates that converted UnitedHealth Group RSUs and stock options will continue to be subject to the same terms and conditions (including vesting and settlement terms) as were applicable to the original Amedisys awards. This implies a continuation of the equity incentive structure under the new parent company.

Industry Context

This filing reflects the completion of a significant merger in the healthcare services industry, where a large diversified healthcare company (UnitedHealth Group) acquired a leading home health and hospice provider (Amedisys). This consolidation trend is common in the healthcare sector, driven by desires for vertical integration, cost efficiencies, and expanded service offerings.

Comparison to Industry Standards

• The conversion of equity awards (RSUs and stock options) into equivalent awards of the acquiring company, with adjusted terms to reflect the merger consideration, is a standard practice in corporate acquisitions. This approach aims to preserve the value and incentive structure for employees of the acquired entity. Specific comparable companies or projects are not detailed in this Form 4, as it focuses on individual ownership changes post-merger.

Stakeholder Impact

• Shareholders (Amedisys): Received $101 per share in cash for their common stock, as per the merger agreement.
• Employees (Amedisys): Those with RSUs and stock options had their awards converted into UnitedHealth Group equity, maintaining their incentive structure under the new parent company.
• UnitedHealth Group: Successfully completed the acquisition of Amedisys, integrating its operations and personnel.

Key Dates

Recommendation

This Form 4 reports a completed transaction (merger) and the subsequent conversion of an officer's equity holdings. It does not provide new information that would alter the investment thesis for Amedisys (which is now a subsidiary) or UnitedHealth Group. The transactions are expected outcomes of the merger. For UnitedHealth Group, this filing is a minor administrative detail following a significant acquisition. For Amedisys, the stock is no longer traded. Therefore, a 'hold' recommendation is appropriate as there's no new actionable information for investors based solely on this filing.

Keywords

Amedisys, AMED, UnitedHealth Group, Merger, Acquisition, Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Equity Compensation, Chief Accounting Officer